ProKidney Corp. (PROK)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
ProKidney Corp. (PROK) trades at $1.99 with AI Score 21/100 (Grade F). ProKidney Corp. is a clinical-stage biotechnology company focused on developing cellular therapy candidates for kidney disease. Market cap: $669.15M, Sector: Healthcare.
Price live · AI analysis from May 9, 2026Analyst Coverage for PROK: PROK does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates PROK against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
PROK: 3/7 perspectives are bullish. Dominant signal: Ken Griffin bullish.
How is this calculated? →ProKidney Corp. (PROK) Healthcare & Pipeline Overview
ProKidney Corp. is a clinical-stage biotechnology firm specializing in cellular therapies for kidney disease, with its lead candidate, Renal Autologous Cell Therapy (REACT), in Phase III trials. Targeting diabetic kidney disease and congenital anomalies, ProKidney aims to address unmet needs in renal care, positioning itself within the competitive biotechnology landscape.
What Is the Investment Thesis for PROK?
ProKidney Corp. presents a notable research candidate within the biotechnology sector, primarily driven by its Renal Autologous Cell Therapy (REACT) candidate. Currently in Phase III trials, REACT targets a significant unmet need in diabetic kidney disease, a market with substantial growth potential. Successful completion of Phase III and subsequent regulatory approval could lead to significant revenue streams. Key value drivers include positive clinical trial outcomes, strategic partnerships, and expansion into new indications such as congenital anomalies of the kidney and urinary tract (CAKUT). However, the company's negative profit margin of -7725.2% and gross margin of -218.8% highlight the risks associated with clinical-stage biotech companies, including potential setbacks in clinical trials and the need for additional funding. The company's beta of 1.86 suggests higher volatility compared to the market.
Based on FMP financials and quantitative analysis
PROK Key Highlights
- Renal Autologous Cell Therapy (REACT) is in Phase III clinical development for diabetic kidney disease, representing a significant potential market opportunity.
- Phase II clinical trials are underway for REACT in treating moderate to severe diabetic kidney disease, expanding the potential patient population.
- Phase I clinical trial is in progress for patients with congenital anomalies of the kidney and urinary tract (CAKUT), diversifying the therapeutic pipeline.
- The company's focus on autologous cell therapy offers a personalized medicine approach, potentially leading to improved patient outcomes.
- ProKidney Corp. maintains a market capitalization of $669.15M, reflecting investor confidence in its technology and clinical programs.
Who Are PROK's Competitors?
PROK is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| TNGX Tango Therapeutics, Inc. | $29.52 | +0.21% | $3.67B | — |
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| ABVX Abivax S.A. | $145.38 | +0.51% | $9.53B | 76 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
| GLUE Monte Rosa Therapeutics, Inc. | $23.06 | -4.75% | $1.50B | 68 |
| RNAM Avidity Biosciences Inc | $72.86 | +0.05% | $11.26B | 68 |
| DAWN Day One Biopharmaceuticals, Inc. | $21.53 | +0.00% | $2.22B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are PROK's Key Strengths?
- Proprietary Renal Autologous Cell Therapy (REACT) platform.
- Advanced stage clinical trials (Phase III) for diabetic kidney disease.
- Focus on autologous cell therapy offers a personalized medicine approach.
- Experienced management team with expertise in biotechnology and nephrology.
What Are PROK's Weaknesses?
- Clinical-stage company with no currently approved products.
- High research and development costs.
- Negative profit margin and gross margin.
- Reliance on successful clinical trial outcomes and regulatory approvals.
What Could Drive PROK Stock Higher?
- Announcement of Phase III clinical trial results for Renal Autologous Cell Therapy (REACT) in diabetic kidney disease (expected in late 2026).
- Potential FDA approval of REACT for diabetic kidney disease (estimated timeline: 2027-2028, contingent on Phase III results).
- Progression of Phase II clinical trials for REACT in moderate to severe diabetic kidney disease.
- Advancement of Phase I clinical trial for REACT in patients with congenital anomalies of the kidney and urinary tract (CAKUT).
What Are the Key Risks for PROK?
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures or delays in the development of Renal Autologous Cell Therapy (REACT).
- Regulatory hurdles and delays in obtaining FDA approval for REACT.
- Competition from established pharmaceutical companies and other biotechnology firms developing kidney disease treatments.
- High research and development costs and the need for additional funding.
- Uncertainty regarding reimbursement policies for REACT and other cell therapies.
What Are the Growth Opportunities for PROK?
- Expansion into New Therapeutic Areas: ProKidney has the opportunity to expand the application of its Renal Autologous Cell Therapy (REACT) platform beyond diabetic kidney disease and congenital anomalies of the kidney and urinary tract (CAKUT). Exploring other kidney-related disorders, such as focal segmental glomerulosclerosis (FSGS) or polycystic kidney disease (PKD), could significantly broaden the addressable market. Each new indication represents a potential multi-billion dollar market, contingent upon successful clinical trials and regulatory approvals. This expansion could occur within the next 3-5 years, contingent on ongoing research and development efforts.
- Strategic Partnerships and Collaborations: ProKidney can pursue strategic partnerships with larger pharmaceutical companies or research institutions to accelerate the development and commercialization of its cellular therapies. Collaborations can provide access to additional funding, expertise, and distribution channels. For instance, partnering with a company specializing in regenerative medicine could enhance ProKidney's technological capabilities. Such partnerships could materialize within the next 1-2 years, depending on the progress of clinical trials and the attractiveness of ProKidney's technology to potential partners.
- Geographic Expansion: ProKidney has the opportunity to expand its clinical trials and, eventually, commercial operations into new geographic markets, particularly in Asia and Europe, where the prevalence of kidney disease is high. Entering these markets would require navigating different regulatory landscapes and establishing local partnerships. The global market for kidney disease treatments is projected to reach $20 billion by 2028, with significant growth expected in emerging markets. Geographic expansion could begin within the next 2-3 years, following successful Phase III trial results and regulatory approvals in the United States.
- Advancements in Cell Therapy Technology: ProKidney can invest in research and development to further enhance its cell therapy technology, improving the efficacy, safety, and scalability of its Renal Autologous Cell Therapy (REACT) platform. This could involve optimizing cell selection, expansion, and delivery methods. Advancements in cell therapy technology could lead to improved patient outcomes and reduced treatment costs, making ProKidney's therapies more competitive. Ongoing research in this area could yield significant breakthroughs within the next 3-5 years.
- Securing Regulatory Approvals and Reimbursement: A crucial growth opportunity for ProKidney lies in successfully navigating the regulatory approval process and securing favorable reimbursement policies for its Renal Autologous Cell Therapy (REACT). Obtaining FDA approval in the United States and EMA approval in Europe would be major milestones, opening up access to large patient populations. Securing favorable reimbursement from government and private payers is also essential to ensure the widespread adoption of REACT. This process is ongoing and could take 1-3 years following the completion of Phase III trials.
What Opportunities Does PROK Have?
- Expansion into new therapeutic areas beyond diabetic kidney disease and CAKUT.
- Strategic partnerships with larger pharmaceutical companies.
- Geographic expansion into Asia and Europe.
- Advancements in cell therapy technology.
What Threats Does PROK Face?
- Clinical trial failures or delays.
- Regulatory hurdles and delays in obtaining approvals.
- Competition from established pharmaceutical companies and other biotechnology firms.
- Changes in reimbursement policies.
What Are PROK's Competitive Advantages?
- Proprietary Renal Autologous Cell Therapy (REACT) platform.
- Advanced stage clinical trials (Phase III) provide a competitive lead.
- Focus on autologous cell therapy offers a personalized medicine approach.
- Strong intellectual property portfolio protecting its technology.
What Does PROK Do?
Founded in 2015 and headquartered in Winston-Salem, North Carolina, ProKidney Corp. is a clinical-stage biotechnology company focused on transforming the treatment of chronic kidney disease (CKD). The company is dedicated to developing innovative cellular therapies designed to improve or restore kidney function. Its primary focus is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture. REACT is currently undergoing a Phase III clinical development program for the treatment of moderate to severe diabetic kidney disease. Additionally, ProKidney is conducting Phase II clinical trials for diabetic kidney disease and Phase I clinical trials for patients with congenital anomalies of the kidney and urinary tract (CAKUT). ProKidney's approach involves using a patient's own kidney cells to promote regeneration and improve kidney function, potentially reducing or eliminating the need for dialysis or kidney transplantation. The company's research and development efforts are centered on addressing the underlying causes of kidney disease, rather than merely managing the symptoms. ProKidney aims to provide a more sustainable and effective treatment option for patients suffering from CKD. The company's focus on cellular therapy places it at the forefront of regenerative medicine within the nephrology space. ProKidney continues to advance its clinical programs and explore new applications for its cellular therapy platform.
What Products and Services Does PROK Offer?
- Develop Renal Autologous Cell Therapy (REACT) for kidney disease.
- Conduct Phase III clinical trials for REACT in diabetic kidney disease.
- Conduct Phase II clinical trials for REACT in moderate to severe diabetic kidney disease.
- Conduct Phase I clinical trials for REACT in patients with congenital anomalies of the kidney and urinary tract (CAKUT).
- Focus on autologous cell therapy using a patient's own kidney cells.
- Aim to improve or restore kidney function and reduce the need for dialysis.
- Engage in research and development to advance cellular therapy technologies.
How Does PROK Make Money?
- Develop and commercialize cellular therapies for kidney disease.
- Generate revenue through the sale of REACT and future cell therapy products.
- Out-license or partner with other companies for development and commercialization.
- Secure funding through venture capital, public offerings, and strategic partnerships.
What Industry Does PROK Operate In?
ProKidney Corp. operates within the biotechnology industry, specifically focusing on cellular therapies for kidney disease. The market for kidney disease treatments is substantial and growing, driven by the increasing prevalence of diabetes and hypertension, major risk factors for CKD. The competitive landscape includes established pharmaceutical companies and other biotechnology firms developing novel therapies for kidney disease. ProKidney's focus on autologous cell therapy differentiates it from competitors offering traditional pharmaceutical or dialysis-based treatments. The biotechnology industry is characterized by high research and development costs, long development timelines, and regulatory hurdles, but also offers the potential for significant returns upon successful commercialization of innovative therapies.
Who Are PROK's Key Customers?
- Patients with diabetic kidney disease.
- Patients with congenital anomalies of the kidney and urinary tract (CAKUT).
- Hospitals and clinics specializing in nephrology.
- Healthcare providers treating kidney disease.
FY2026 estForward Outlook
Wall Street analysts project ProKidney Corp. revenue of about $511K for fiscal 2026, with EPS near $-0.64. The estimate reflects 5 contributing analysts.
F-Score 1/9Financial Health
ProKidney Corp.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 6.73 places it in the safe zone, indicating low near-term bankruptcy risk.
ROE 7%Key Financial Metrics
Return on equity for ProKidney Corp. stands at 7.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -25.6%, showing how much profit it generates from its asset base. Its free cash flow yield is -22.7%, a gauge of the cash the business throws off relative to its market value. A current ratio of 9.06 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -26.8%, the inverse of the P/E and a quick read on earnings relative to price.
ProKidney Corp. (PROK) Valuation Context
Valued at $669.15M, PROK is classified as a small-cap stock. Relative to its peer group, PROK's quantitative score of 21/100 is below the peer average of 78/100.
Company Profile
ProKidney Corp. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Winston-Salem, US. The company is led by CEO Bruce Culleton. PROK has traded publicly since 2021.
PROK Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in ProKidney's future, indicating that executives believe in the company's potential growth.
- Community sentiment has been increasingly positive, with discussions highlighting ProKidney's innovative approaches in kidney disease treatment.
- Analysts have noted the growing demand for kidney health solutions, positioning ProKidney favorably within a niche market.
- Recent partnerships and collaborations have been well-received, enhancing ProKidney's credibility and market presence.
Bear Case
- Concerns over regulatory hurdles in the healthcare sector may impact ProKidney's operational timeline and market entry.
- Some community members express skepticism about the scalability of ProKidney's technology, citing potential challenges in widespread adoption.
- Recent market volatility has led to a cautious sentiment, with some investors questioning the sustainability of ProKidney's growth trajectory.
- Competitive pressures from established players in the kidney health space could pose significant challenges for ProKidney's market share.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · January 2026
PROK Latest News
-
AEVEX, Abivax, Watts Water Technologies And Other Big Stocks Moving Higher On Tuesday
benzinga · Jun 30, 2026
-
Biohaven, Goodyear Tire And Other Big Stocks Moving Lower In Monday’s Pre-Market Session
benzinga · Jun 29, 2026
-
HC Wainwright & Co. Reiterates Buy on ProKidney, Maintains $12 Price Target
benzinga · May 18, 2026
-
ProKidney Q1 EPS $(0.14), Inline, Sales $226.000K Beat $143.667K Estimate
benzinga · May 15, 2026
PROK Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for PROK.
Price Targets
Wall Street price target analysis for PROK.
PROK MoonshotScore
What does this score mean?
The MoonshotScore rates PROK's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Latest News
AEVEX, Abivax, Watts Water Technologies And Other Big Stocks Moving Higher On Tuesday
Biohaven, Goodyear Tire And Other Big Stocks Moving Lower In Monday’s Pre-Market Session
HC Wainwright & Co. Reiterates Buy on ProKidney, Maintains $12 Price Target
ProKidney Q1 EPS $(0.14), Inline, Sales $226.000K Beat $143.667K Estimate
Latest ProKidney Corp. Analysis
Leadership: Bruce Culleton
CEO
Bruce Culleton is the CEO of ProKidney Corp., bringing extensive experience in the healthcare and biotechnology industries. His background includes various leadership roles in pharmaceutical and medical device companies. He has a proven track record in strategic planning, business development, and commercialization of innovative healthcare products. Culleton's expertise spans across multiple therapeutic areas, including nephrology, and he has a deep understanding of the regulatory landscape and market dynamics within the healthcare sector. He is responsible for managing 204 employees.
Track Record: Under Bruce Culleton's leadership, ProKidney Corp. has advanced its Renal Autologous Cell Therapy (REACT) program into Phase III clinical trials. He has overseen the expansion of the company's clinical pipeline and the strengthening of its intellectual property portfolio. Culleton has also been instrumental in securing funding and establishing strategic partnerships to support the company's growth. His focus on innovation and patient-centricity has driven ProKidney's mission to transform the treatment of chronic kidney disease.
Common Questions About PROK (Healthcare)
What does ProKidney Corp. do?
ProKidney Corp. is a clinical-stage biotechnology company focused on developing cellular therapies for the treatment of chronic kidney disease (CKD). Their lead product candidate, Renal Autologous Cell Therapy (REACT), is an autologous cell therapy currently in Phase III clinical trials for diabetic kidney disease. REACT utilizes a patient's own kidney cells to promote regeneration and improve kidney function, potentially reducing or eliminating the need for dialysis or kidney transplantation. The company also has ongoing Phase I and Phase II trials for other kidney-related conditions, demonstrating a commitment to expanding the applications of their technology.
What do analysts say about PROK stock?
Analyst coverage of ProKidney Corp. is still emerging, given its clinical-stage nature. Key valuation metrics are heavily influenced by the potential success of REACT in Phase III trials and subsequent regulatory approval. Growth considerations center on the large and growing market for kidney disease treatments, particularly in diabetic kidney disease. Analyst sentiment is cautiously optimistic, pending further clinical data and regulatory milestones. However, the high risk associated with clinical-stage biotech companies is acknowledged, particularly concerning potential setbacks in clinical trials and the need for future financing.
What are the main risks for PROK?
The primary risks for ProKidney Corp. revolve around the inherent uncertainties of clinical-stage drug development. Clinical trial failures or delays in the REACT program would significantly impact the company's prospects. Regulatory hurdles and potential delays in obtaining FDA approval also pose a substantial risk. Competition from established pharmaceutical companies and other biotechnology firms developing kidney disease treatments could limit ProKidney's market share. Furthermore, the company faces financial risks associated with high research and development costs and the need for additional funding to support its clinical programs. Uncertainty regarding reimbursement policies for REACT and other cell therapies adds another layer of risk.
How does ProKidney Corp. navigate regulatory approval processes?
ProKidney Corp. is actively engaging with regulatory agencies, such as the FDA in the United States, to ensure compliance and facilitate the approval process for its Renal Autologous Cell Therapy (REACT). The company's strategy involves conducting rigorous clinical trials, adhering to Good Manufacturing Practices (GMP), and maintaining open communication with regulatory authorities. ProKidney is also focused on generating comprehensive data packages to support its regulatory submissions. The company's regulatory track record is still developing, as it awaits its first potential FDA approval for REACT. A successful regulatory strategy is crucial for the commercialization of ProKidney's therapies.
What are the key growth opportunities for PROK in healthcare?
ProKidney Corp.'s key growth opportunities lie in expanding the application of its Renal Autologous Cell Therapy (REACT) platform to new therapeutic areas within kidney disease, such as focal segmental glomerulosclerosis (FSGS) and polycystic kidney disease (PKD). Geographic expansion into markets with high prevalence of kidney disease, particularly in Asia and Europe, also presents a significant growth opportunity. Furthermore, strategic partnerships with larger pharmaceutical companies or research institutions could accelerate the development and commercialization of REACT. Advancements in cell therapy technology and securing favorable reimbursement policies are also critical for driving growth. These opportunities align with the increasing demand for innovative and effective treatments for kidney disease.
What are the key factors to evaluate for PROK?
ProKidney Corp. (PROK) holds an AI score of 21/100 (low). Not financial advice.
How frequently does PROK data refresh on this page?
PROK prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven PROK's recent stock price performance?
ProKidney Corp. (PROK) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary Renal Autologous Cell Therapy (REACT) platform. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- Clinical trial outcomes are inherently uncertain.
- Regulatory approvals are not guaranteed.